Recruiting Studies
Baxduo-PACIFIC
Baxduo-PACIFIC: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific)
More information: clinicaltrials.gov Investigational product: Baxdrostat Population:eGFR ≥30 and <60 mL/min/1.73 m2 with UACR between 3.39 mg/mmol and 56.5 mg/mmol, or eGFR ≥30 and ≤75 mL/min/1.73 m2 with UACR between 56.5 mg/mmol and ≤565 mg/mmol or UPCR between 79 mg/mmol and 790 mg/mmol
Phase: III Starting year: 2025 Participating sites: Albert Schweitzer hospital (Dordrecht), Amsterdam UMC, Isala (Zwolle), LUMC (Leiden), Meander Medisch Centrum (Amersfoort), MUMC+ (Maastricht), St. Antonius (Nieuwegein), Tergooi MC (Hilversum), UMCG (Groningen) National lead: prof.dr. M.H. de Borst (UMCG)PROMISE
PROMISE: Potassium correction for RAAS optimization in chronic kidney disease
More information: clinicaltrials.gov
Investigational product: Patiromer
Population: Stage 3b-4 CKD with ACR >3 mg/mmol
Phase: IV
Starting year: 2024
Participating sites: Amsterdam UMC, Frisius MC (Leeuwarden), Isala (Zwolle), UMCG (Groningen)
National lead: prof.dr. M.H. de Borst (UMCG)
PODOMOUNT-pFSGS
PODOMOUNT-pFSGS, a Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants
More information: clinicaltrials.gov
Investigational product: BI 764198 (TRPC6 inhibitor)
Population: Patients aged ≥12 years with biopsy-proven primary FSGS or genetic FSGS caused by a TRPC6 mutation, UPCR ≥1500 mg/g and eGFR ≥25 mL/min/1.73 m².
Phase: III
Starting year: 2026
Participating sites: UMC Groningen (actively recruiting), Amsterdam UMC (pending activation)
Referral note: Due to limited recruitment timelines, referral of potentially eligible patients from non-participating centres is encouraged. Patients can be referred to the participating sites for screening and potential inclusion.
PODOMOUNT-Basket
PODOMOUNT-Basket, a Phase II, Multicentre, Randomised, 2-arm Parallel-group, Double-blind, Placebo-controlled Basket Trial to Assess Safety, Tolerability, PK, and Efficacy of BI 764198 in Four Proteinuric Kidney Diseases
More information: clinicaltrials.gov
Investigational product: BI 764198 (TRPC6 inhibitor)
Population: Male or female participants ≥18 years old (≥12 years old for TR-pMCD and Alport Syndrome excluding the EU) with one of the following proteinuric kidney diseases:
- maladaptive secondary FSGS
- treatment-resistant primary minimal change disease (MCD)
- Alport syndrome
- treatment-resistant primary membranous nephropathy (MN)
with eGFR ≥25 mL/min/1.73 m² and persistent proteinuria despite standard of care.
Phase: II
Starting year: 2026
Participating sites: UMC Groningen (actively recruiting), Amsterdam UMC (pending activation)
Referral note: Due to limited recruitment timelines, referral of potentially eligible patients from non-participating centres is encouraged. Patients can be referred to the participating sites for screening and potential inclusion.
Follow-up Studies
K+ in CKD trial
K+ in CKD trial
More information: clinicaltrials.gov
Investigational product: Potassium chloride / potassium citrate
Population: Stage 3b-4 CKD with ACR >3 mg/mmol
Phase: III
Starting year: 2017
National lead: prof.dr. E.J. Hoorn (Erasmus MC)
Contact NEFRO-NL
How can we help?
Would you like to know more about NEFRO-NL, our research network or our services? Our project managers will be happy to help. Contact us at info@nefro-nl.nl.
Antina de Boer
project manager
